{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:38:41Z","timestamp":1791639521617,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"name":"Military Infectious Diseases Research Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dengue is a global health problem and the development of a tetravalent dengue vaccine with durable protection is a high priority. A heterologous prime-boost strategy has the advantage of eliciting immune responses through different mechanisms and therefore may be superior to homologous prime-boost strategies for generating durable tetravalent immunity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this phase 1 first-in-human heterologous prime-boost study, 80 volunteers were assigned to 4 groups and received a tetravalent dengue virus (DENV-1\u20134) purified inactivated vaccine (TDENV-PIV) with alum adjuvant and a tetravalent dengue virus (DENV-1\u20134) live attenuated vaccine (TDENV-LAV) in different orders and dosing schedules (28 or 180 days apart).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All vaccination regimens had acceptable safety profiles and there were no vaccine-related serious adverse events. TDEN-PIV followed by TDEN-LAV induced higher neutralizing antibody titers and a higher rate of tetravalent seroconversions compared to TDEN-LAV followed by TDEN-PIV. Both TDEN-PIV followed by TDEN-LAV groups demonstrated 100% tetravalent seroconversion 28 days following the booster dose, which was maintained for most of these subjects through the day 180 measurement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A heterologous prime-boost vaccination strategy for dengue merits additional evaluation for safety, immunogenicity, and potential for clinical benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02239614.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa603","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T04:33:09Z","timestamp":1600489989000},"page":"1707-1716","source":"Crossref","is-referenced-by-count":26,"title":["Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial"],"prefix":"10.1093","volume":"223","author":[{"given":"Leyi","family":"Lin","sequence":"first","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Koren","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher M","family":"Paolino","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H","family":"Eckels","sequence":"additional","affiliation":[{"name":"Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"De La Barrera","sequence":"additional","affiliation":[{"name":"Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Friberg","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Currier","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D","family":"Gromowski","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi E","family":"Aronson","sequence":"additional","affiliation":[{"name":"Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B","family":"Keiser","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J","family":"Sklar","sequence":"additional","affiliation":[{"name":"Naval Medical Research Center, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L","family":"Sondergaard","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis E","family":"Jasper","sequence":"additional","affiliation":[{"name":"US Army Medical Materiel Development Activity, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P","family":"Endy","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University, Institute for Global Health and Translational Sciences, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"Jarman","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Thomas","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"2021052811194856900_CIT0001","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2021052811194856900_CIT0002","article-title":"Dengue vaccine: global development update","author":"Prompetchara","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2021052811194856900_CIT0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/vaccines8010063","article-title":"A review on dengue vaccine development","volume":"8","author":"Deng","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2021052811194856900_CIT0004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/21645515.2016.1261770","article-title":"Vaccines licensed and in clinical trials for the prevention of dengue","volume":"13","author":"Torresi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2021052811194856900_CIT0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/infdis\/jiq060","article-title":"The necessity and quandaries of dengue vaccine development","volume":"203","author":"Thomas","year":"2011","journal-title":"J Infect Dis"},{"key":"2021052811194856900_CIT0006","author":"US Food and Drug Administration"},{"key":"2021052811194856900_CIT0007","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"2021052811194856900_CIT0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"2021052811194856900_CIT0009","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"2021052811194856900_CIT0010","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2019.01956","article-title":"Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus?","volume":"10","author":"Vald\u00e9s","year":"2019","journal-title":"Front Immunol"},{"key":"2021052811194856900_CIT0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"2021052811194856900_CIT0012","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4269\/ajtmh.15-0659","article-title":"Long-term safety and immunogenicity of a tetravalent live-attenuated dengue vaccine and evaluation of a booster dose administered to healthy Thai children","volume":"94","author":"Watanaveeradej","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2021052811194856900_CIT0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4269\/ajtmh.13-0452","article-title":"Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial","volume":"91","author":"Watanaveeradej","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2021052811194856900_CIT0014","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4269\/ajtmh.14-0819","article-title":"Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial","volume":"93","author":"Martinez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2021052811194856900_CIT0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2021052811194856900_CIT0016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4269\/ajtmh.14-0625","article-title":"A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in Puerto Rico","volume":"93","author":"Bauer","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2021052811194856900_CIT0017","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","article-title":"An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in Rhesus macaques","volume":"92","author":"Fernandez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2021052811194856900_CIT0018","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3389\/fimmu.2019.01778","article-title":"Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003","volume":"10","author":"Waickman","year":"2019","journal-title":"Front Immunol"},{"key":"2021052811194856900_CIT0019","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa603\/34121612\/jiaa603.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/10\/1707\/38360116\/jiaa603.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/10\/1707\/38360116\/jiaa603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T12:21:12Z","timestamp":1622204472000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/10\/1707\/5910633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2021,5,28]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa603","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,15]]},"published":{"date-parts":[[2020,9,23]]}}}